N/A N=256 Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: 3-year Overall Survival Rate — 67.9; 68.4 percentage of participants — p=0.32
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=82 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
Breast Cancer
Primary: Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC. — 1; 8; 3; 11 Participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
Phase 2 N=23 Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 — 0…
Phase 2 N=76 S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Survival at 1 Year — 93 percentage of patients
Phase 2 N=27 S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
Breast Cancer
Primary: Confirmed Response Rate (Complete and Partial) — 2 participants
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Phase 2 N=17 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Phase 2 N=112 S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Response Rate (Complete and Partial, Confirmed and Unconfirmed) — 29 participants
Phase 2 N=41 Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Breast Cancer
Primary: Three-year Relapse-free Survival — 61.5; 77.8 percentage of participants
Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 2 N=25 Partial Breast Irradiation With Chemotherapy
Breast Cancer
Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 2 N=33 Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathologic Complete Response (pCR) — 6 patients
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 1 N=11 Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: The Number of Participants Who Experienced Dose-limiting Adverse Events — 1; 0 participants
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 2 N=36 Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 4.3 months
Phase 3 N=799 Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Progression Free Survival — 10.97; 9.3; 7.36 months — p=0.054
Phase 2 N=32 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: 5-Year Relapse-free Survival Rate — 53 percentage of participants
N/A N=46 4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer
Breast Cancer
Primary: Patients With Reduction in Incidental Radiation — 46 Participants
Phase 2 N=68 Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Inflammatory Breast Cancer · Male Breast Cancer · Stage II Breast Cancer
Primary: Microscopic Pathologic CR (pCR) Rate — 27 percent of evaluable participants
Phase 2 N=50 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Estrogen Receptor-negative Breast Cancer · Estrogen Receptor-positive Breast Cancer · Inflammatory Breast Cancer
Primary: Event-free Survival — 11; 9 Participants
Phase 3 N=394 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
Invasive Breast Carcinoma · Recurrent Breast Carcinoma · Stage III Breast Cancer AJCC v6
Primary: Progression-free Survival — 20.2; 15.6 months
Phase 3 N=5,351 Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
Breast Cancer
Primary: Overall Survival — 83; 79; 79 percentage of patients alive
Phase 2 N=76 Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Antitumor Activity Based on Time to Tumor Progression (TTP). — 9.3 months
N/A N=30 Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Breast Cancer
Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants